{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T07:18:56Z","timestamp":1773299936615,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2007,11,6]],"date-time":"2007-11-06T00:00:00Z","timestamp":1194307200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1038\/sj.bjc.6604074","type":"journal-article","created":{"date-parts":[[2007,11,7]],"date-time":"2007-11-07T05:59:34Z","timestamp":1194415174000},"page":"1499-1504","source":"Crossref","is-referenced-by-count":34,"title":["Activity of endovesical gemcitabine in BCG-refractory bladder cancer patients: a translational study"],"prefix":"10.1038","volume":"97","author":[{"given":"R","family":"Gunelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Bercovich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O","family":"Nanni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Ballardini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G L","family":"Frassineti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Giovannini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Fiori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Pasquini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Ulivi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G L","family":"Pappagallo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Silvestrini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W","family":"Zoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,11,6]]},"reference":[{"key":"BF6604074_CR1","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1200\/JCO.1991.9.3.491","volume":"9","author":"JL Abbruzzese","year":"1991","unstructured":"Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, Mineishi S, Tarassoff P, Satterlee W, Raber MN (1991) A Phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 9: 491\u2013498","journal-title":"J Clin Oncol"},{"key":"BF6604074_CR2","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.urology.2005.04.062","volume":"66","author":"R Bartoletti","year":"2005","unstructured":"Bartoletti R, Cai T, Gacci M, Giubilei G, Viggiani F, Santelli G, Repetti F, Nerozzi S, Ghezzi P, Sisani M, TUR (Toscana Urologia) Group (2005) Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a phase 2 prospective multicenter study. Urology 66: 726\u2013731","journal-title":"Urology"},{"key":"BF6604074_CR3","first-page":"2381","volume":"25","author":"F Campodonico","year":"2005","unstructured":"Campodonico F, Canepa G, Capponi G, Bozzo L, Maffezzini M (2005) Intravesical gemcitabine in recurrent superficial bladder carcinoma: preliminary results on ablative efficacy and tolerability. Anticancer Res 25: 2381\u20132384","journal-title":"Anticancer Res"},{"key":"BF6604074_CR4","first-page":"2629","volume":"5","author":"PJ Cozzi","year":"1999","unstructured":"Cozzi PJ, Bajorin DF, Tong W, Nguyen H, Scott J, Heston WD, Dalbagni G (1999) Toxicology and pharmacokinetics of intravesical gemcitabine: a preclinical study in dogs. Clin Cancer Res 5: 2629\u20132637","journal-title":"Clin Cancer Res"},{"key":"BF6604074_CR5","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1200\/JCO.2005.05.2720","volume":"24","author":"G Dalbagni","year":"2006","unstructured":"Dalbagni G, Russo P, Bochner B, Ben-Porat L, Sheinfeld J, Sogani P, Donat MS, Herr HW, Bajorin D (2006) Phase II trial of intravesical gemcitabine in bacille Calmette-Guerin-refractory transitional cell carcinoma of the bladder. J Clin Oncol 24: 2729\u20132734","journal-title":"J Clin Oncol"},{"key":"BF6604074_CR6","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1200\/JCO.2002.02.066","volume":"20","author":"G Dalbagni","year":"2002","unstructured":"Dalbagni G, Russo P, Sheinfeld J, Mazumdar M, Tong W, Rabbani F, Donat MS, Herr HW, Sogani P, dePalma D, Bajorin D (2002) Phase I trial of intravesical gemcitabine in Bacillus Calmette-Guerin-refractory transitional-cell carcinoma of the bladder. J Clin Oncol 20: 3193\u20133198","journal-title":"J Clin Oncol"},{"key":"BF6604074_CR7","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/j.1464-410X.2003.04656.x","volume":"93","author":"E De Berardinis","year":"2004","unstructured":"De Berardinis E, Antonini G, Peters GJ, Loves WJ, Van der Born K, Codacci-Pisanelli G, Di Silverio F (2004) Intravesical administration of gemcitabine in superficial bladder cancer: a phase I study with pharmacodynamic evaluation. BJU Int 93: 491\u2013494","journal-title":"BJU Int"},{"key":"BF6604074_CR8","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1097\/00000478-199812000-00001","volume":"22","author":"J Epstein","year":"1998","unstructured":"Epstein J, Amin M, Reuter V, Mostofi F (1998) The World Health Organization\/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Path 22: 1435\u20131448","journal-title":"Am J Surg Path"},{"key":"BF6604074_CR9","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.eururo.2004.05.001","volume":"46","author":"P Gontero","year":"2004","unstructured":"Gontero P, Casetta G, Maso G, Sogni F, Pretti G, Zitella A, Frea B, Tizzani A (2004) Phase II study to investigate the ablative efficacy of intravesical administration of gemcitabine in intermediate-risk superficial bladder cancer (SBC). Eur Urol 46: 339\u2013343","journal-title":"Eur Urol"},{"key":"BF6604074_CR10","first-page":"117","volume":"48","author":"DH Kern","year":"1988","unstructured":"Kern DH, Morgan CR, Hildebrand-Zanki SU (1988) In vitro pharmacodynamics of 1-beta-D-arabinofuranosylcytosine: synergy of antitumor activity with cis-diamminedichloroplatinum(II). Cancer Res 48: 117\u2013121","journal-title":"Cancer Res"},{"key":"BF6604074_CR11","first-page":"533","volume":"51","author":"Y Kohjimoto","year":"2005","unstructured":"Kohjimoto Y, Iba A, Shintani Y, Uekado Y, Shinka T (2005) Treatment of Bacillus Calmette-Guerin refractory superficial bladder cancer: further intravesical therapy. Hinyokika Kiyo 51: 533\u2013538","journal-title":"Hinyokika Kiyo"},{"key":"BF6604074_CR12","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1200\/JCO.2003.09.028","volume":"21","author":"M Laufer","year":"2003","unstructured":"Laufer M, Ramalingam S, Schoenberg MP, Haisfield-Wolf ME, Zuhowski EG (2003) Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study. J Clin Oncol 21: 697\u2013703","journal-title":"J Clin Oncol"},{"key":"BF6604074_CR13","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1200\/JCO.2005.05.089","volume":"20","author":"J Li","year":"2005","unstructured":"Li J, Juliar B, Yiannoutsos C, Ansari R, Fox E, Fisch MJ, Einhorn LH, Sweeney CJ (2005) Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study. J Clin Oncol 20: 1185\u20131191","journal-title":"J Clin Oncol"},{"key":"BF6604074_CR14","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0959-8049(98)00030-6","volume":"34","author":"V Lorusso","year":"1998","unstructured":"Lorusso V, Pollera CF, Antimi M, Luporini G, Gridelli C, Frassineti GL, Oliva C, Pacini M, De Lena M (1998) A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur J Cancer 34: 1208\u20131212","journal-title":"Eur J Cancer"},{"key":"BF6604074_CR15","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1159\/000052377","volume":"37","author":"P Malmstrom","year":"2000","unstructured":"Malmstrom P (2000) Improved patient outcomes with BCG immunotherapy vs. chemotherapy: Swedish and worldwide experience. Eur Urol 37: 16\u201320","journal-title":"Eur Urol"},{"key":"BF6604074_CR16","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/S0022-5347(01)61607-0","volume":"161","author":"PU Malmstrom","year":"1999","unstructured":"Malmstrom PU, Wijkstrom H, Lundhholm C, Wester K, Busch C, Norlen BJ (1999) Five-year followup of a randomized prospective study comparing mitomycin C and Bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. J Urol 161: 1124\u20131127","journal-title":"J Urol"},{"key":"#cr-split#-BF6604074_CR17.1","unstructured":"1. Oosterlinck W, Van der Meijden A, Sylvester R, B\u00f6hle E, Rintala E, Solsona Narv\u00f3n E, Lovel B (2006) European Association of Urology"},{"key":"#cr-split#-BF6604074_CR17.2","unstructured":"2. (EAU): Guidelines on TaT1 (non muscle-invasive) bladder cancer (2006) -   www.uroweb.org\/fileadmin\/user_upload\/Guidelines\/05%20TaT1%20Bladder%20Cancer.pdf"},{"key":"BF6604074_CR18","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s002800050755","volume":"41","author":"S Romanelli","year":"1998","unstructured":"Romanelli S, Perego P, Pratesi G, Carenini N, Tortoreto M, Zunino F (1998) In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems. Cancer Chemother Pharmacol 41: 385\u2013390","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF6604074_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10: 1\u201310","journal-title":"Control Clin Trials"},{"key":"BF6604074_CR20","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1093\/jnci\/82.13.1107","volume":"13","author":"P Skehan","year":"1990","unstructured":"Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR (1990) New colorimetric cytotoxic assay for anticancer drug screening. J Natl Cancer Inst 13: 1107\u20131112","journal-title":"J Natl Cancer Inst"},{"key":"BF6604074_CR21","volume-title":"TNM Classification Malignant Tumours","author":"LH Sobin","year":"1997","unstructured":"Sobin LH, Wittekind CH (eds) (1997) TNM Classification Malignant Tumours 5th edn. John Wiley & Sons, Inc: New York"},{"key":"BF6604074_CR22","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","volume":"168","author":"RJ Sylvester","year":"2002","unstructured":"Sylvester RJ, van der Meijden AP, Lamm DL (2002) Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168: 1964\u20131970","journal-title":"J Urol"},{"key":"BF6604074_CR23","doi-asserted-by":"publisher","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","volume":"23","author":"H Von Der Maase","year":"2005","unstructured":"Von Der Maase H, Seugelov L, Roberts JT, Roberts JT, Ricci S, Dogliotti L, Oliver T, Moore MJ, Zimmermann A, Arning M (2005) Long-term survival of a randomized trial comparing gemcitabine plus cisplatin with methotrexate\u2013vinblastine\u2013doxorubicin plus cisplatin in patients with bladder cancer. J Clin Oncol 23: 4602\u20134608","journal-title":"J Clin Oncol"},{"key":"BF6604074_CR24","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S1040-8428(00)00110-4","volume":"37","author":"W Zoli","year":"2001","unstructured":"Zoli W, Ricotti L, Tesei A, Barzanti F, Amadori D (2001) In vitro preclinical models for a rational design of chemotherapy combinations in human tumors. Crit Rev Oncol Hematol 37: 69\u201382","journal-title":"Crit Rev Oncol Hematol"},{"key":"BF6604074_CR25","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1158\/1078-0432.CCR-1107-03","volume":"10","author":"W Zoli","year":"2004","unstructured":"Zoli W, Ricotti L, Tesei A, Ulivi P, Gasperi Campani A, Fabbri F, Gunelli R, Frassineti GL, Amadori D (2004) Schedule-dependent cytotoxic interaction between epidoxorubicin and gemcitabine in human bladder cancer cells in vitro. Clin Cancer Res 10: 1500\u20131507","journal-title":"Clin Cancer Res"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6604074.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6604074","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6604074.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:29:51Z","timestamp":1684412991000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6604074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11,6]]},"references-count":26,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["BF6604074"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6604074","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,11,6]]}}}